Akebia Therapeutics, Inc. (AKBA) Balance Sheet
As of 2026-06-30 (10-Q), Akebia Therapeutics, Inc. (AKBA) reported total assets of $349.7M, total liabilities of $324.6M and shareholders' equity of $25.0M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $155.5M. Long-term debt: $24.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKBAAkebia Therapeutics, Inc.Follow AKBA — free
—
Price chart with a free account
- Market cap
- 157.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 32.8 | 49.8 | 187.3 | 70.2 | 104.6 | 147.4 | 228.7 | 149.8 | 90.5 | 42.9 | 51.9 | 184.8 | 155.5 | |
| Short-term investments | 36.3 | 39.1 | 65.1 | 217.9 | 216.8 | 0.2 | — | — | — | — | — | — | — | |
| Receivables | 0.0 | — | 33.8 | 34.2 | 16.7 | 38.9 | 26.9 | 51.6 | 40.3 | 39.3 | 34.4 | 47.0 | 53.5 | |
| Inventory | — | — | — | — | 114.2 | 116.3 | 61.0 | 36.6 | 21.6 | 15.7 | 16.2 | 15.6 | 13.0 | |
| Current assets | 110.5 | 141.0 | 296.3 | 358.4 | 468.3 | 309.5 | 371.4 | 271.1 | 185.2 | 118.1 | 113.8 | 253.0 | 229.6 | |
| Total assets | 111.0 | 142.9 | 300.2 | 364.2 | 996.5 | 771.2 | 644.1 | 529.3 | 356.1 | 241.7 | 220.7 | 376.6 | 349.7 | |
| Current liabilities | 6.9 | 11.9 | 114.3 | 141.1 | 265.7 | 208.1 | 187.1 | 261.1 | 129.5 | 99.9 | 80.9 | 162.9 | 160.9 | |
| Long-term debt | — | — | — | — | — | 75.8 | 96.4 | 0.0 | 34.1 | 17.2 | 38.7 | 48.3 | 24.8 | |
| Short-term debt | — | — | — | — | 15.0 | — | 0.0 | 97.5 | 32.0 | 17.5 | 0.0 | 0.0 | 24.8 | |
| Total liabilities | 6.9 | 11.9 | 232.1 | 241.7 | 360.6 | 376.4 | 396.5 | 455.3 | 350.8 | 272.3 | 269.9 | 344.0 | 324.6 | |
| Shareholders' equity | 104.1 | 131.0 | 68.1 | 122.6 | 635.9 | 392.9 | 244.4 | 74.0 | 5.2 | -30.6 | -49.2 | 32.6 | 25.0 |
USD millions · SEC XBRL
Akebia Therapeutics, Inc. — questions
- How much cash does Akebia Therapeutics, Inc. have?
- $155.5M in cash and cash equivalents as of 2026-06-30.
- How much debt does Akebia Therapeutics, Inc. have?
- $24.8M of long-term debt and $24.8M due within a year as of 2026-06-30.
- What are Akebia Therapeutics, Inc.'s total assets?
- $349.7M as of 2026-06-30.
- What is Akebia Therapeutics, Inc.'s shareholders' equity?
- $25.0M as of 2026-06-30.
Every figure on this page comes from Akebia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.